Gram-negative and Gram-positive bacteria release a variety of membrane vesicles through different formation routes. Knowledge of the structure, molecular cargo and function of bacterial extracellular vesicles (BEVs) is primarily obtained from bacteria cultured in laboratory conditions. BEVs in human body fluids have been less thoroughly investigated most probably due to the methodological challenges in separating BEVs from their matrix and host-derived eukaryotic extracellular vesicles (EEVs) such as exosomes and microvesicles. Here, we present a step-by-step procedure to separate and characterize BEVs from human body fluids. BEVs are separated through the orthogonal implementation of ultrafiltration, size-exclusion chromatography (SEC) and density-gradient centrifugation. Size separates BEVs from bacteria, flagella and cell debris in stool; and blood cells, high density lipoproteins (HDLs) and soluble proteins in blood. Density separates BEVs from fibers, protein aggregates and EEVs in stool; and low-density lipoproteins (LDLs), very-lowdensity lipoproteins (VLDLs), chylomicrons, protein aggregates and EEVs in blood. The procedure is label free, maintains the integrity of BEVs and ensures reproducibility through the use of automated liquid handlers. Post-separation BEVs are characterized using orthogonal biochemical endotoxin and Toll-like receptor-based reporter assays in combination with proteomics, electron microscopy and nanoparticle tracking analysis (NTA) to evaluate BEV quality, abundance, structure and molecular cargo. Separation and characterization of BEVs from body fluids can be done within 72 h, is compatible with EEV analysis and can be readily adopted by researchers experienced in basic molecular biology and extracellular vesicle analysis. We anticipate that this protocol will expand our knowledge on the biological heterogeneity, molecular cargo and function of BEVs in human body fluids and steer the development of laboratory research tools and clinical diagnostic kits.
Introduction
The secretion of proteins, nucleotides, lipids and other factors is a vital process in all living organisms and is important for inter-kingdom interactions in health and disease 1 . The human intestinal tract is constantly exposed to environmental antigens and vast quantities of commensal bacteria that generally live in a symbiotic and mutually beneficial relationship with their host. Accumulating evidence shows that these interactions influence, at least in part, cancer, mental health, and cardiovascular and immune disorders [2] [3] [4] [5] .
Short-and long-distance interaction between bacteria and the host occurs through direct contacts and secreted products, such as (quorum-sensing) peptides, proteins, nucleic acids, lipoglycans and membrane vesicles, also termed bacterial extracellular vesicles 6 . The first evidence of extracellular vesicle secretion by Gram-negative bacteria was obtained in the 1960s (refs. 7, 8 ). The existence of extracellular vesicles produced by Gram-positive bacteria was reported 30 years later 9 . Gram-negative bacteria have two main routes of vesicle formation: blebbing of the outer membrane of the bacterial envelope, forming outer membrane vesicles, or explosive cell lysis, generating outer-inner membrane vesicles or explosive outer membrane vesicles. Bubbling of Gram-positive bacteria gives rise to cytoplasmic membrane vesicles 7 . Independent of their biogenesis pathways, all membrane vesicles are hereafter referred to as BEVs. BEVs released by Gram-negative bacteria are characterized by an interior leaflet of phospholipids and an exterior leaflet of lipopolysaccharide (LPS), which activates immune cells through Toll-like receptor (TLR) 4 (ref. 7 ). Gram-positive bacteria, and thus also their BEVs, show surface lipoteichoic acid (LTA), which activates immune cells through TLR2 (ref. 10 ). The variety in membrane envelope structure and biogenesis route results in the production of BEVs of various size, density and molecular cargo. In close parallel to EEVs, which include exosomes, microvesicles and apoptotic bodies, BEVs are heterogeneous. The production and relative distribution of BEV subtypes depend on the bacterial species and their physiological state 11 . Most of the knowledge of BEV biogenesis, structure, molecular cargo and function is obtained from extensive studies using bacteria cultured in laboratory conditions. Analysis of human body fluids has become one of the most promising approaches to discovering biomarkers and revealing pathophysiological mechanisms, but is inherently challenging because of its complexity. EEVs have been identified in many human body fluids, including blood. Because EEVs contain a sample of the cellular content, including proteins, nucleic acids and other analytes, EEVs have been increasingly explored in a quest to enable easy and efficient diagnosis and monitoring of disease progression and therapy response-with potential applications in cancer diagnostics being one example of imminent use 12 . Although the colonization of specific body sites in contact with the external environment (such as the gastrointestinal tract) by bacteria is universally accepted 13 , the study of BEVs in body fluids, including blood, is a new concept. BEVs have been observed in cerebrospinal fluid and blood plasma from patients with clinically severe bacterial infections 14, 15 , in stool from healthy donors 16 and in gastric biopsy specimens from Helicobacter pylori-infected patients 17 . The identification of the biological heterogeneity, molecular cargo and function of BEVs that prevail in each particular body fluid, however, requires protocol development to allow reproducible analysis of BEVs. We have recently developed a protocol that integrates orthogonal biophysical separation with biochemical characterization to analyze BEVs in human blood plasma and stool. Using this protocol, we succeeded in identifying BEVs in blood plasma of non-septic patients, with concentrations ranging from 10 5 to 10 6 BEVs per ml of blood plasma. Importantly, we showed that BEVs from blood plasma are able to induce immune activation and that the systemic presence of BEVs associates with increased permeability of the intestinal epithelial barrier 6 . To steer reproducible analysis of BEVs in human body fluids, which is required to further unravel the biological properties and explore the clinical potential of these specific entities, we here present a step-by-step procedure to separate and characterize BEVs. We hope that our protocol will circumvent the problem that lack of awareness of the co-separation of BEVs with EEVs, lipoproteins, soluble proteins, flagella and protein aggregates may lead to wrong conclusions about the molecular cargo and functions of BEVs [18] [19] [20] [21] .
Overview of the protocol
Orthogonal biophysical separation of BEVs A plethora of methods have become available to separate extracellular vesicles from different biofluids, including human body fluids. The majority of these methods use biophysical or biochemical characteristics of extracellular vesicles, such as size, density and surface molecules. The specificity of the separation method for extracellular vesicles is determined by the complexity of the starting material and thus the overlap of biophysical and biochemical characteristics of extracellular vesicles with other biological components that prevail in the particular body fluid. Because different body fluids have a highly variable compositions, each protocol to recover extracellular vesicles from body fluids may require specific protocol steps. The size and density distributions of diverse biological components of blood and stool are shown in Fig. 1 . In blood, BEVs overlap, at least in part, in size (size range~50-250 nm) with EEVs, protein aggregates, VLDLs, LDLs and chylomicrons. In stool, BEVs overlap, at least in part, in size with EEVs and protein aggregates, and partially overlap with pili and flagellar fragments in density. To separate BEVs with high specificity from blood plasma and stool, we developed a protocol that orthogonally implements size-based and density-based methods with some body fluid-specific modifications. The workflow of the orthogonal biophysical separation of BEVs from blood plasma and stool is outlined in Fig. 2 and is described further below.
After collection and resuspension of the stool sample in endotoxin-free PBS, a crude extract is prepared by ultrafiltration, which allows cell debris, fibers, pili and flagella >0.22 µm to be adequately removed. The crude extract is mixed with a high-density iodixanol solution and overlaid with step gradients of low-density iodixanol solutions. Bottom-up density-gradient centrifugation allows further separation of BEVs from other biological components present in the crude extract, including low-molecular-weight proteins and small fibers that are denser and/or do not float and thus remain in the bottom fractions of the gradient. Next, BEVs are retrieved from density fractions by SEC, which removes iodixanol-which may interfere with biochemical characterization-and remnants of other biological components such as flagellar fragments. Iodixanol (OptiPrep) is the most frequently used density-gradient medium for BEV separation from bacterial cell cultures because it is iso-osmotic at useful concentrations, preventing damage of sensitive membranous structures 22 .
For blood samples, after collection, platelet-depleted plasma is prepared and a crude extract is obtained by SEC, which allows HDLs and low-molecular-weight proteins to be depleted. The crude extract is layered on top of the density gradient (top-down density-gradient centrifugation) to further separate BEVs from other biological components present in the crude extract, including EEVs, VLDLs, LDLs and chylomicrons that are less dense and thus remain in the top fractions of the density gradient. BEVs are retrieved from density fractions by SEC.
Orthogonal biochemical and functional characterization of BEVs Characterization of BEV preparations by multiple complementary methods is important to evaluating the likelihood that identified molecular cargo and functions are associated with BEVs and not other biological components. In addition, each method contributes specific insights into biological heterogeneity, abundance, structure, molecular cargo and function. In this protocol, post-separation BEVs are characterized using endotoxin and TLR-based reporter assays in combination with proteomics, electron microscopy and NTA (Fig. 3) . The implementation of a biochemical endotoxin (Limulus amebocyte lysate (LAL)) and TLR reporter assays in combination with NTA allows the total number of BEVs as well as the relative abundance of Gram-positive (LTA assessed by TLR2 assay) versus Gram-negative BEVs (LPS assessed by TLR4 and LAL assays) to be quantified. Mass spectrometry-based proteomics, western blot analysis and ELISA assays identify outer-and innermembrane proteins and cytosolic proteins associated with BEV, but also non-BEV components, such as lipoprotein-associated apoA-I and EEV-associated proteins. Human peripheral blood mononuclear cells (PBMCs) are used as an ex vivo test model to investigate the immune modulatory impact of BEVs.
Applications
We demonstrated in our previous publication for the first time that BEVs reside in blood; that their numbers associate with increased permeability of the intestinal epithelial barrier in HIV, inflammatory bowel disease (IBD) and chemotherapy-treated cancer patients; and that they harbor the capacity to activate PBMCs in an ex vivo assay 6 . Importantly, we showed that orthogonal biophysical separation is necessary and sufficient to characterize BEVs, as evidenced by the lack of association between other LPS products, such as LPS neutralized by lipoproteins and endotoxin core antibodies, and the permeability of the intestinal epithelial barrier 6 . The protocol can be adapted for an array of body fluids from human or any other species, given their similar matrix complexity. BEV separation from other body fluids may, however, require , detailed in Box 2, by orthogonal biophysical methods. a, After collection and preparation of the stool sample, a crude extract is prepared by ultrafiltration. BEVs are separated and recovered from this extract using the combination of a bottom-up density gradient and SEC. b, After collection of the blood sample, platelet-depleted plasma is prepared and a crude extract is obtained by SEC. BEVs are separated and recovered from this extract using the combination of a top-down density gradient and SEC. The expected BEV concentration is given per gram of stool sample (with a BSS category of 3 or 4) or milliliter of blood plasma. Steps requiring sample volume reduction are indicated with an asterisk. In addition, we present alongside a color coded scale to show BEV enrichment of stool and blood plasma relative to body fluid-specific contaminants.
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inclusion or optimization of specific protocol steps. To allocate biomarkers and functions to BEVs, lower-and higher-density fractions or smaller-size fractions can be included in control experiments. Furthermore, results from low-biomass samples are prone to misinterpretation due to the potential presence of contaminating molecules derived from laboratory reagents and environments. Thus, the possibility of contaminants demands careful evaluation and appropriate controls 23 . In parallel to BEV analysis, the protocol supports the analysis of EEVs that reside in the studied body fluid, because density-gradient centrifugation from crude extracts separates EEVs (1.083-1.111 g/ml) from higherdensity BEVs (1.133-1.201 g/ml) with high specificity. Step 29B
LPS
Step 29C
Step 29D
Step 29E
Step 29G
Step 29F 
NATURE PROTOCOLS
PROTOCOL
This protocol yields integrated information on the size, buoyant density, quantity, relative abundance of Gram-negative and Gram-positive BEVs, ultrastructure, molecular cargo and function of BEVs. By combining these characteristics, BEV subsets can be mapped within stool and blood plasma, and by extension other body fluids, which will undoubtedly expand our knowledge of the biological heterogeneity and function of BEVs in body fluids. Ensuring reproducibility through the implementation of automated liquid handlers allows associations of the quantity and molecular cargo of BEVs with multiple disease conditions to be investigated, which will inherently support the clinical application of BEVs as biomarkers of disease. Last but not least, we envision that this protocol can serve as a reference in the further development and optimization of methods for separating and characterizing BEVs. A unique advantage of the protocol is the high specificity toward BEVs, which allows BEV characteristics such as zeta potential, surface molecules, buoyant density and size to be unraveled and can be exploited for the development of laboratory research tools and clinical diagnostic kits.
Taken together, we anticipate that the protocol will stimulate research on BEVs in body fluids, an exciting research domain that yet remains largely unexplored. The applications and target audience are broad, including research fields covering biomarkers, liquid biopsies, microbiome, extracellular vesicles, membrane vesicles, disease areas characterized by increased intestinal barrier permeability (such as HIV, IBD, cancer) and technical fields focusing on separation of macromolecular biomolecules.
Comparison with other methods
A plethora of separation methods have become available to retrieve extracellular vesicles from different biofluids, including body fluids. The majority of these methods use biophysical or biochemical characteristics of extracellular vesicles, such as size (differential ultracentrifugation, asymmetric-flow field-flow fractionation, SEC, ultrafiltration), buoyant density (density-gradient centrifugation) or surface molecules (primarily proteins; immune affinity capture) 21 . The working mechanisms, advantages and limitations of these methods have been recently reviewed 19 . The specificity of the separation method for extracellular vesicles is determined by the complexity of the starting material and the overlap of biophysical and biochemical characteristics with other biofluid components. Indeed, biophysical characteristics are not unique to extracellular vesicles. Protein aggregates and lipoproteins, among other biological components, have a size or density range similar to that of extracellular vesicles. Traditional one-step physical-based methods have been successfully implemented to separate extracellular vesicles from cell culture supernatant with high specificity 18 but are not sufficient to separate extracellular vesicles from body fluids 6, 19 . Immune-affinity capture exploits the biochemical surface composition to separate extracellular vesicles with a high specificity but requires knowledge of surface antigens (which is not yet available for BEVs residing in body fluids), inherently selecting for subpopulations and interfering with functional analysis because of antibody binding. Step 29E) and proteomic analysis (Step 29G)). BEV subtypes include OMVs, OIMVs and CMVs. The BEV concentration required to perform a particular technique is represented as a function of all the approaches (see graph in the middle of the figure) . The presence of certain proteins is revealed by western blot analysis and a BEV size distribution profile is obtained by NTA. After PBMC stimulation, a wide array of chemokines and cytokines are released, in contrast to non-stimulated PBMCs. Within the detection range of the PAMP characterization assays, a linear relationship exists between LPS (EU/ml), TLR2 or TLR4 activity (OD 630 nm) and BEV concentration (data points of three technical replicates and error bars (s.d.) are represented; LAL: Pearson's r = 0.9994; TLR2: Pearson's r = 0.9145; TLR4: Pearson's r = 0.9814). Immuno-electron microscopy is performed using anti-LPS antibodies. The results shown for the techniques marked with an asterisk were obtained by using stool-derived BEVs; the others were obtained by using Absolute BEV counting could be aided by appropriate reference materials and is most informative for separation methods with high specificity, such as the orthogonal biophysical separation presented in this protocol. As biological reference material, we propose trackable recombinant extracellular vesicles, such as those developed by our group 24 . Alternative characterization methods to those presented in this protocol can be implemented, as long as these methods ensure the combined assessment of single BEVs using two complementary methods and the detection of both BEV-associated proteins and non-BEV-associated proteins, in compliance with the MISEV2018 guidelines 25 .
Limitations
The sequential implementation of a size-based method to reduce body fluid complexity and a density-based method is necessary and sufficient to separate BEVs from other biological components residing in body fluids. However, no single protocol can be universally applied for the analysis of different body fluids as illustrated in this protocol for blood plasma and stool. The separation method must be adapted on the basis of the complexity (i.e., sample volume and composition) of the body fluid of interest.
A second limitation of orthogonal biophysical separation is the need for two sequential separation methods, including density-gradient centrifugation, which hampers high-throughput processing of human body fluids for BEV analysis. Density-gradient centrifugation is, however, critical to separate BEVs with high specificity from other biological components of body fluids, such as lipoproteins, protein aggregates, fibers and EEVs. A similar level of specificity cannot be achieved with other separation methods available to date. Importantly, implementation of fully automated densitygradient preparation and fraction collection renders density-gradient centrifugation highly reproducible, operator independent, robust and less time consuming.
The stringency of the criteria used to select the size and density fractions will determine the specificity and efficiency of BEV recovery from body fluids. This protocol was developed to recover BEVs with high specificity, which is needed to map the biochemical and biophysical characteristics of BEVs. Rational criteria for the selection of these size and density fractions are determined in function of (i) maximizing BEV recovery and (ii) minimizing the level of cross-contamination with other biological components (e.g., co-isolation of EEVs). The required stringent collection of these fractions will result in loss of some BEVs. The heterogeneity of BEV density, owing to differences in, for example, environmental conditions, bacterial growth phase and species 11, [26] [27] [28] , may thus result in the exclusion of BEVs that have lower densities, overlapping with EEVs. While establishing the protocol, we recommend that researchers evaluate all size and density fractions in order to identify the fractions containing the BEVs of particular interest and then calculate their size and density. These observations are driven by in vitro studies. Implementation of our protocol may reveal whether these fluctuations in size and density range are reflected in BEVs residing in human body fluids.
Relevant issues, such as standardization of sample collection, handling and storage of human body fluids for the study of BEVs, have not been addressed. For blood plasma, we recommend following the standard operating procedures provided in the MISEV2018 guidelines 25 . For stool samples, we recommend following the standard operating procedures provided by the International Human Microbiome Standards (IHMS) project 29 . Comparative studies of sample collection and storage are, however, warranted to create reliable biorepositories for the study of BEVs in body fluids.
Experimental design
Sample collection
A variety of experimental parameters are inherently associated with body fluid collection, handling and storage (e.g., type of container, time to storage, storage temperature and transport) and will directly impact the recovery and integrity of BEVs. The IHMS project has developed standard operating procedures for stool collection and handling for DNA analysis 29 . Several publications have listed recommendations for blood collection and handling for the analysis of EEVs 20, 30, 31 . To date, the effects of these experimental parameters on different classes of extracellular vesicles, including BEVs, are unclear. In this protocol, we perform and transparently report on body fluid collection, handling and storage according to the current state of the art to ensure protocol reproducibility (Box 1; refs. 20, 21, 25 ). Sterile endotoxin-free materials must be used for all steps. An overview of sample collection is provided in Fig. 2 .
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The choice between fresh and frozen body fluids is determined by a laboratory's accessibility to fresh body fluids and capacity for immediate orthogonal biophysical separation and biochemical characterization. Sample collection, handling and storage must be performed identically for comparative studies of BEVs (Fig. 4 ). The total volume of blood plasma or mass of stool sample required is determined by the number and type of downstream characterizations. Furthermore, because numerous host and environmental factors are reported to influence the microbiome, hypothesisdriven metadata collection-providing donor information on antibiotic (or other therapeutic) interventions, dietary intake and a range of other markers of health-must be considered.
In the Procedure, we provide a protocol for collecting and analyzing stool samples as an example. Stool samples are collected in sterile, wide-mouth containers, refrigerated (4°C), kept in ice packs during transport and delivered by the donor to the clinician within 24 h after defecation, in accordance with the legal requirements of the country and the guidelines of the institution (Step 1). General recommendations from laboratories routinely performing stool collection can be applied. Stool consistency measurements using the Bristol Stool Scale (BSS) are performed to allow confounder analysis, because stool consistency influences bacterial species richness or community composition 32 . The time interval between stool collection and preparation should be minimized, or at least be kept constant, between samples to limit effects on the concentration and functional activity of BEVs.
In Box 2, we then highlight the changes to the Procedure that are necessary in order to apply it to the analysis of blood samples. Donor blood is drawn by venipuncture into sterile citrate tubes by a trained physician or nurse, in accordance with the legal requirements of the country and the guidelines of the institution (Box 2). General recommendations from laboratories routinely performing blood collection can be applied. Plasma is usually the preferred source of EEVs because additional vesicular structures are released during clot formation when preparing serum. At present, citrate is the anticoagulant most commonly used to study EEVs, and the use of citrate blood collection tubes has been recommended by the International Society on Thrombosis and Haemostasis 30 . The time interval between blood collection and blood plasma preparation should be minimized, or at least be kept constant between samples, to limit effects on the concentration and functional activity of BEVs.
Sample preparation
An overview of sample preparation is provided in Fig. 2 . We recommend that all steps be carried out in a laminar flow cabinet to avoid contaminations. Sterile, endotoxin-free materials must be used for all steps.
Stool samples are resuspended in endotoxin-free PBS and depleted of large components, such as bacteria, cell debris, dead leukocytes and undigested material, by implementing a two-step centrifugation at 8,000g for 15 min at 4°C (Steps 2-7). Because this centrifugation does not exclude the presence of bacterial contamination in the prepared stool sample, we recommend continuing directly to crude extract preparation (Steps 8-15).
Blood plasma must be processed to deplete platelets and blood cells by implementing a two-step centrifugation at 2,500g for 15 min at room temperature (19°C) (Box 2). Plasma depleted from platelets can be divided into single-use aliquots to avoid freeze-thaw cycles and can be stored at −80°C. Freeze-thaw cycles and short-term storage of blood plasma may impact BEV concentration, integrity and molecular composition because of cargo leakage. Box 1 | Transparent reporting of BEV studies using EV-TRACK Transparent reporting is a prerequisite for the successful interpretation and reproducibility of published experiments. We strongly encourage researchers to add experimental parameters to the EV-TRACK knowledgebase 21 . EV-TRACK is a free online toolset (http://evtrack.org) that centralizes EV biology and methodology with the goal of stimulating authors, reviewers and editors to put experimental guidelines into practice, enhancing the performance, characterization and reporting of BEV-related research. The EV-METRIC represents a checklist with which to assess the completeness of reporting of the generic and method-specific information necessary to interpret and reproduce an experiment. Currently, only 3.62% of all studies uploaded into EV-TRACK are BEV related, with a mean EV-METRIC of 21.9%. The use of density-based separation is reported in 29.0% of these studies, and in more than 17% of the BEV studies, no characterization of the separated vesicles is performed.
Orthogonal biophysical separation of BEVs
BEVs (~50-250 nm) are smaller than bacteria (~1 µm) and larger than HDLs (~10 nm), and small and large low-molecular-weight proteins and lipids (<5 nm) 19 . Fibers and protein aggregates can be present in a wide range of sizes (>1 nm; Fig. 1 ). According to these physical properties, we implement size-based methods leading to a separation of BEVs from these components but resulting in coseparation with LDLs, VLDLs, chylomicrons, protein aggregates and EEVs in blood plasma, and small fibers, low-molecular-weight proteins, protein aggregates and EEVs in stool ( Fig. 2 ; Steps 8-15).
To increase the specificity toward BEVs, we sequentially exploit another intrinsic physical property of extracellular vesicles, namely density. BEVs (1.133-1.201 g/ml) differ in buoyant density from LDLs, VLDLs, chylomicrons (1.041-1.083 g/ml), protein aggregates, low-molecular-weight proteins and fibers (±1.4 g/ml) and EEVs (1.083-1.111 g/ml) ( Fig. 1 ; ref. 19 ). Submitting the crude extract to robot-assisted density-gradient centrifugation achieves a high specificity for BEVs while minimizing co-separation of other biological components ( Fig. 2; Steps [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] .
Multiple size-based methods are available to prepare a crude extract from a body fluid. A SEC column packed with cross-linked Sepharose 2B beads is used to reduce viscosity of body fluids prior a b c
Step 3 Sample saturation
Step 28
Step 1 to BEV separation. SEC enables the separation of particles on the basis of their molecular size because of their differential ability to percolate through pores of a given column matrix. In general, larger particles are excluded from the pores and pass through more rapidly (elute first from the column), whereas smaller particles will migrate through these pores, prolonging their transit through the matrix. The ability to separate particles of a given size range is determined by the pore size of the c CRITICAL STEP Because the BEV concentration in blood samples is low, and the final detection techniques are very sensitive, it is of utmost importance to avoid any kind of bacterial or endotoxin contamination. Therefore, we replace gradient buffers A and B with endotoxin-free PBS to exclude potential contamination caused by these reagents. 8 Perform Step 18 of the Procedure. Replace the gradient buffer B with endotoxin-free PBS. In addition, also prepare a 5% (wt/vol) iodixanol solution by mixing 0.5 ml of the working solution with 4.5 ml of endotoxin-free PBS. 9 Prepare a density gradient similar to those in Step 20 of the Procedure, but use a slightly modified density-gradient structure, as follows:
carefully Step 29B of the Procedure) using, for example, anti-LPS antibodies. In this case, incubation of the grids in blocking solution (1% BSA in endotoxin-free PBS) is critical in order to reduce aspecific binding. The blocking efficiency must be controlled by performing the labeling procedure in the absence of primary antibody. Western blot analysis can be performed to detect EEV (markers: Flotillin-1, CD9 and ALIX) and lipoprotein contamination (HDL marker: apoA-I).
As with BEV separation from stool samples, we recommend performing a blank BEV separation starting from 2 ml of endotoxin-free PBS and performing the characterization techniques (described in step 14 of this box) on the final sample. This sample serves as a protocol control and will allow detection of any contamination. PROTOCOL NATURE PROTOCOLS exclusion matrix, for example, Sepharose 2B has a pore size of ≈60 nm (ref. 20 ). As for other sizebased techniques, SEC fractions containing BEVs should be empirically identified for each body fluid 33, 34 . Multiple SEC fractions containing BEVs can be combined to increase recovery efficiency. The input sample volume for SEC is restricted, rendering the method less suitable for large-volume body fluids such as prepared stool. For blood plasma, SEC returns a crude extract, depleted of HDLs and small low-molecular-weight proteins. Ultrafiltration using 0.22-μm filters returns a crude extract from stool, depleted of fibers, large protein aggregates and undigested food. The crude extracts are further concentrated by centrifugal filters with cellulose membrane and 10-kDa pore size 35 . Both crude extracts are characterized by a high efficiency (i.e., minimal loss of BEVs) but low specificity for BEVs. Crude extracts can be frozen at −80°C until further use.
Crude extracts obtained from stool and blood plasma are subjected to density-gradient centrifugation, a separation method that depends on the size and mass density (top-down gradient) or mass density only (bottom-up gradient) of particles. Different body fluids require different approaches with regard to the sample loading approach and choice of density range. The crude extract can be mixed with the densest fraction and loaded at the bottom of the tube (bottom-up approach) or the crude extract can be loaded on top of the density gradient (top-down approach). A bottom-up density gradient is often preferred for the separation of extracellular vesicles because only vesicular structures are able to float upward into the gradient. However, this approach is inferior for the separation of BEVs from blood plasma, because abundantly present LDLs, VLDLs and chylomicrons, with a lower density than that of BEVs, also float through the BEV density fraction of interest when using a bottom-up approach. In our experience, this inevitably leads to a reduced specificity for BEVs. To ensure separation of BEVs from other biological components in stool, a 50% (wt/vol) iodixanol layer is added to the bottom-up gradient. HEPA-enclosed automated liquid handlers enable reproducible, robust and contaminant-free density-gradient separation, and their use is encouraged in preference to manual density-gradient preparation and fraction collection.
Density-gradient centrifugation of crude extracts obtained from stool and blood plasma returns a BEV sample with a low efficiency (i.e., a substantial loss of BEVs) but high specificity for BEVs. BEVs can be analyzed after removal of the density media by an additional SEC step, which is recommended to further increase specificity (i.e., a substantial removal of fibers and flagella; Fig. 4c ) and to avoid interference of the density medium with functional assays, electron microscopy and mass spectrometry-based proteomics 35 (Step 28) .
General methods for the characterization of BEVs
Post-separation BEVs are characterized in compliance with EV-TRACK and MISEV2018 guidelines 21, 25 ( Step 29; Fig. 3 ). Each preparation of BEVs should be (i) defined by quantitative and qualitative measures of the source (e.g., mass and type of stool, volume of blood plasma and type of blood collection tube; see Step 2); (ii) characterized to determine abundance and quality of BEVs (e.g., by NTA to determine total particle number and by electron microscopy to visualize BEV ultrastructure, BEV integrity and potential co-separation of components; see Step 29A and 29B); (iii) tested for presence of content associated with BEVs (e.g., proteomics, western blot and LPS-and LTA-based assays; see Step 29C-G); and (iv) tested for the absence of other components (e.g., proteomics, western blot and ELISA assays for lipoproteins, including apoA-I (HDLs) and apo B variants (LDLs, VLDLs, chylomicrons); see Step 29C and 29G. Because the final BEV concentration can be a limiting factor in performing all these general characterization methods (in addition to other functional assays), we advise-in agreement with the EV-TRACK and MISEV2018 guidelines 21,25full assessment and characterization of BEV preparations for each new experimental design developed in the lab. On a routine basis, a limited set of characterization methods can be used to define BEV preparations (e.g., NTA and western blot).
Transmission electron microscopy (TEM), combined with mass spectrometry-based proteomics, is able to confirm the specificity of the protocol for BEVs. Western blot and ELISA analysis can be used to further confirm the presence of a limited number of membrane-associated BEV proteins and the lack of some contaminating particles such as EEVs and lipoproteins. BEV markers implemented in this protocol are not universally expressed across all bacterial species. The choice of BEV and contaminant markers will rely on the research aim, bacterial species of interest and type of body fluid. Quantification methods such as NTA are the most informative for extracellular vesicles recovered by separation techniques with the highest specificity because these methods are not specific to BEVs and also register other co-separated biological materials including lipoproteins and protein aggregates. Therefore, in compliance with the MISEV2018 guidelines, we recommend including complementary methods to assess whether quantification provides an adequate estimation of BEV number and size. Absolute extracellular vesicle sizing and counting methods are currently imperfect and will require further improvement, aided by appropriate reference standards such as those developed by our group 24 . Nevertheless, current methods can provide a reasonable indication of the number of particles per volume, and particle size distributions that are best interpreted when combined with general (e.g., western blot analysis for positive and negative protein markers) and single-particle analyses (e.g., electron microscopy (close-up and wide field)). Other methods to characterize BEVs are available and applicable beside those implemented in this protocol including but not limited to flow cytometry, tunable resistive pulse sensing, cryo-electron microscopy, atomic force microscopy, dynamic light scattering and single-particle interferometric reflectance imaging. An accurate quantitation of BEVs is possible only within a certain concentration and size range that varies by platform.
Orthogonal biochemical characterization of BEVs
We have adopted highly sensitive assays that are routinely used to detect pyrogens in pharmaceuticals and medical devices ( Fig. 3 ; ref. 36 ). Pathogen-associated molecular patterns (PAMPs) are recognized by a number of cellular sensors of the innate immunity, which include TLRs. Reporter assays based on the use of stably TLR-transfected HEK293 cells have been designed to provide a sensitive and reliable method for the detection of TLR agonists. HEK-Blue/hTLR2 and HEK-Blue/hTLR4 cells coexpress a specific TLR gene and a TLR-inducible reporter gene encoding the secreted embryonic alkaline phosphatase (SEAP), allowing TLR stimulation to be monitored. While TLR4 mediates the inflammatory response to LPS (Gram-negative BEVs), TLR2 is more specifically involved in the detection of LTA (Gram-positive BEVs). The LAL assay is an alternative characterization technique that uses the blood of the horseshoe crab Limulus polyphemus to quantify LPS.
Note that positive assay results can be generated by other bacterial or host components. As a consequence, endotoxin reporter assays are most informative for BEVs recovered with high specificity. Analysis of electron microscopy images at high resolution and mass spectrometry-based proteomics of separated BEVs from stool and blood plasma further support the specificity of recovered BEVs and the identification of BEV subtypes.
Control samples
We recommend the use of control samples to assess endotoxin contamination and to evaluate the performance of orthogonal biophysical separation and biochemical characterization: 1 Blank sample (negative control). Biochemical characterization of blank sample (e.g., endotoxin-free PBS) versus blank sample processed by orthogonal biophysical separation allows endotoxin contamination to be identified at the level of separation and characterization. The source of contamination can be diverse, ranging from endotoxin-positive reagents to non-sterile equipment. Step 20B. The manual preparation of density gradients can be easily practiced by adding 50 µl of 0.4% (wt/vol) trypan blue solution to the 40% and 10% (wt/vol) iodixanol solutions. A clear distinction between the different layers in this colored test density gradient should be visible. (Fig. 5c) Step 27B. The manual collection of the density-gradient fractions can be practiced by using a colored test gradient (see above). Ensure that no liquid from the next fraction is pipetted up (visual check by color). Notice that the performance of the robot-assisted density gradient handling can also be evaluated using this method.
Step 28A. Spike at least 1 × 10 10 EcN BEVs into 2 ml of plasma or PBS and perform SEC (see Box 4 for the preparation of EcN BEVs). The competence of the researcher in the performance of the technique can be evaluated by LPS activity measurement of the SEC fractions from the spiked sample. A first peak should be visible in SEC fractions 4-6, and western blot (using anti-LPS or anti-OmpA antibodies) can further validate these results ( Supplementary Fig. 2) .
Step 28B. Because the pellet after ultracentrifugation can be easily disturbed, extensive training in the careful removal of the supernatant is recommended. Start the supernatant removal with 1,000-µl pipette tips, and switch to 100-µl tips when the remaining volume in the centrifugation tube is approximately 1 ml. Fluorescence labeling of BEVs can be an added value in practicing this step because a pellet with high concentrations of fluorescently labeled BEVs is visible to the naked eye 45 
Reagent setup
Gradient buffer A
To prepare 1 liter of buffer, dissolve 0.25 M sucrose, 6 mM EDTA and 60 mM Tris in 800 ml of endotoxin-free water (use magnetic stirrer). Adjust the pH to 7.4 with HCl (6 M). Dilute the buffer to 1 liter with endotoxin-free water. Filter the buffer with a 0.22-µm bottle-top filter. The buffer can be stored at 4°C for up to 6 months. Prepare the buffer at least 1 d before use, because the complete dissolution of the compounds can take several hours.
c CRITICAL Tris and EDTA are known to interfere with the organization of LPS in bacterial cell membranes 37 . Tris and EDTA concentrations reported in our protocol and others 38 do not impact BEV membrane structure, as evidenced by electron microscopy, presence of intraluminal proteins and consistency of LPS measurement assays. Validation by comparative evaluation of density-gradient buffers (Tris-EDTA versus HEPES-NaCl) is needed in the field to objectively assess technology performance 12 .
Gradient buffer B
To prepare 1 liter of buffer, dissolve 0.25 M sucrose, 1 mM EDTA and 10 mM Tris in 800 ml of endotoxin-free water (use magnetic stirrer). Adjust the pH to 7.4 with HCl (6 M). Dilute the buffer to 1 liter with endotoxin-free water. Filter the buffer using a 0.22-µm bottle-top filter. The buffer can be stored at 4°C for up to 6 months. Prepare at least 1 d before use, because the complete dissolution of the compounds can take several hours.
c CRITICAL Tris and EDTA are known to interfere with the organization of LPS in bacterial cell membranes 37 . Tris and EDTA concentrations reported in our protocol and others 38 do not impact BEV membrane structure, as evidenced by electron microscopy, presence of intraluminal proteins and consistency of LPS measurement assays. Validation by comparative evaluation of density-gradient buffers (Tris-EDTA versus HEPES-NaCl) is needed in the field to objectively assess technology performance 12 . 
Sample-reducing buffer
LB medium
Weigh the following reagents: 10 g of tryptone, 5 g of yeast extract and 5 g of NaCl. Dissolve them in 950 ml of dH 2 O and adjust the pH to 7.3, if necessary, by adding either HCl or NaOH solution. Bring the volume to 1 liter with dH 2 O and sterilize by autoclaving for 15 min at 121°C. LB can be stored at 4°C for up to 1 month.
Methylcellulose-uranyl acetate solution
Add 0.4 g of methylcellulose to 20 ml of boiling endotoxin-free water. Stir for 4-8 h on ice. Add 80 mg of uranyl acetate. Let stand for at least 24 h at 4°C. Store at 4°C for up to 1 month.
Equipment setup
SEC column
Wash the Sepharose beads three times by performing gravity sedimentation (wait at least 2 h to obtain complete sedimentation) and decanting the upper liquid. Replace the liquid each time with endotoxin-free PBS (1 volume of PBS per 2 volumes of beads) and mix thoroughly. Place a quarter of a Nylon-net filter with a 20-µm pore size on the bottom of a 10-ml syringe. Add 10 ml of washed Sepharose beads to the syringe. Make sure the column never becomes dry. Close the lower opening of the syringe with a stopper and the upper opening with Parafilm. Columns can be stored at 4°C for up to 1 week.
NTA
Calibrate the NanoSight LM10 instrument with known concentrations of 100-nm silica microspheres to obtain optimum acquisition detector settings and post-acquisition settings. Record three 60-s videos and analyze them with camera level 13 and detection threshold 3. However, variations between different NTA instruments may occur, so a critical assessment of the settings is required for each instrument.
Procedure c
CRITICAL We provide the procedure below for collection and analysis of stool samples as an example. See Box 2 for details of how to apply the procedure to the analysis of blood samples.
Sample collection • Timing 5 min
1 Collect stool in an opaque, wide-mouth container (with integrated spoon, optionally). We recommend measuring stool consistency with the BSS. This protocol is optimized for stool samples with a BSS category of 3 or 4. Differences in BSS scores impact the stool species' richness 32 , suspension efficiency (Step 3) and BEV recovery. ! CAUTION Experiments using human samples must conform to local and national regulations. In this study, collection of stool samples was done according to Ethical Committee of Ghent University Hospital approval EC/2006/377 and in accordance with the relevant guidelines. Informed consent must be obtained when using patient stool samples. c CRITICAL STEP Freeze-thaw cycles and short-term storage of stool impact BEV concentrations (Fig. 4a ). In addition, a change in BEV integrity and composition due to cargo leakage cannot be excluded. Researchers are required to develop standard operating procedures for studies intended to create reliable biorepositories of stool samples. Data in this protocol were obtained with fresh stool samples.
Sample preparation • Timing 1 h 10 min c
CRITICAL For considerations in regard to sterility and the risk of endotoxin contamination, all further steps are performed in a laminar flow cabinet (class II or III). The use of sterile gloves (with low endotoxin levels) is recommended. 2 Use the spoon to transfer a minimal amount of stool (e.g., 5 g) to a pre-weighed 50-ml tube. 3 Add pre-warmed (37°C) endotoxin-free PBS (e.g., 50 ml) to the tube and suspend the stool sample by constant 360°rotation (in a RotoFlex for 30 min at 37°C; Fig. 5a ). During this step, cool the high-speed centrifuge and JA-10 rotor to 4°C. c CRITICAL STEP Sufficient speed and duration of rotation are essential to ensuring complete suspension of the stool sample. In addition, too high a stool/PBS ratio leads to saturation during suspension and a relatively lower yield of BEVs (Fig. 4b) . A maximum sample concentration of 10% (wt/vol) is recommended (e.g., dissolve 5 g of stool in ≥50 ml of PBS). c CRITICAL STEP We recommend also preparing a blank sample (e.g., endotoxin-free PBS) for orthogonal biophysical separation followed by biochemical characterization as described in Step 29. This blank sample serves as a control and allows any contamination to be detected. 4 Transfer the suspended stool sample to a sterile centrifugation cup. 5 Place the centrifugation cup into the high-speed centrifuge and centrifuge at 8,000g for 15 min at 4°C. Symmetrically balance the load and use a counterbalance when needed. 6 Collect the supernatant, using a serological pipette and an electronic pipettor, and transfer it to a new sterile centrifugation cup. c CRITICAL STEP Avoid transferring or disturbing any pellet, because these contain contaminating material such as fibers, bacteria, undigested food. 7 Place the new centrifugation cup into the high-speed centrifuge and centrifuge at 8,000g for 15 min at 4°C. Symmetrically balance the load and use a counterbalance when needed. c CRITICAL STEP Avoid transferring or disturbing any pellet, because these contain contaminating material such as fibers, bacteria, undigested food. 10 Turn on the vacuum pump and wait until all the sample has passed through the filter and has been collected in the glass bottle. ? TROUBLESHOOTING 11 Use a serological pipette and electronic pipettor to place the filtrate into the concentrate cup of a 10-kDa Millipore Centricon Plus-70 centrifugal filter unit. 12 Centrifuge the filter unit at 3,000g for at least 30 min at 4°C until the sample is concentrated to at least 667 µl (≈1 cm of remaining sample; this can be checked visually). See Step 19 for the rationale behind this volume. Symmetrically balance the load and use a counterbalance when needed. c CRITICAL STEP Frequent visible checking of the concentrate at several time points (e.g., 30, 40 and 45 min) is critical in order to avoid too extensive concentration of the sample, because this will decrease BEV quality and quantity. 13 According to the usage guidelines provided by Millipore, turn the concentrate cup upside down and place it on top of the sample filter cup. 14 Place in the benchtop centrifuge and spin at 1,000g for 2 min at 4°C. Symmetrically balance the load and use a counterbalance when needed. Step 10
Step 20
Step 28 Steps 20 and 27
Step-by-step visualization of the BEV separation protocol. a, In Step 3, the stool sample is suspended in PBS by constant 360°rotation using the RotoFlex. b, To obtain a final crude extract from the stool sample, the sample is passed through a bottle-top filter with a pore size of 0.22 µm (Step 10). Ensure that the filter is firmly screwed onto the bottle and attached to a vacuum pump. Place the bottle on ice. c, In Step 20, a density gradient is prepared as a first step to separate BEVs from the crude extract. We recommend robot-assisted preparation of density gradients (option A) but also provide a manual method (option B). To practice this step, add trypan blue solution to the 40% and 10% (wt/vol) iodixanol solutions (see Box 3) . A clear delineation should be visible between the different layers. d, An illustrative overview of the Biomek 400 automated workstation, which can be used for the preparation and fraction collection of density gradients. e, In Step 28, SEC can be used for the recovery of BEVs. The SEC column is placed in a tripod, and fractions can be collected in Eppendorf tubes.
(≈1.4 ml of gradient buffer A + 7 ml of OptiPrep). Prepare fresh working solution for each experiment. 18 Prepare the 10%, 20% and 40% (wt/vol) iodixanol solutions according to the following table (a 20% excess in stock volume has already been taken into account). Prepare fresh solutions for each experiment and store them on ice in anticipation of further use. See 'Reagent setup' section for the detailed description of the preparation of gradient buffer B. ? TROUBLESHOOTING 20 For the preparation of density gradients, we recommend the robot-assisted preparation technique (option A). This state-of-the-art approach increases protocol repeatability and contributes to operator-independent BEV separation. However, we also provide a step-by-step procedure for manual preparation of density gradients in case an automated liquid handler is not available (option B).
(A) Robot-assisted preparation of density gradients • Timing 20 min per set of three density gradients c CRITICAL To ensure sterility during the preparation of density gradients, we recommend using an automatic liquid handler equipped with a positive-pressure HEPA enclosure. (i) Start the robot (e.g., a Biomek 400 automated workstation) and software. (ii) Open the density-gradient script. The script was designed in close collaboration with Beckman Coulter. (iii) Place the tip boxes, pre-cooled iodixanol solutions reservoir, pipettor, sample rack and pre-cooled tube rack with the centrifugal tube in one of the 12 deck positions of the workstation (Fig. 5d ). (iv) Fill the reservoir with the freshly made iodixanol solutions from Steps 18 and 19.
(v) Start the density-gradient script. (Supplementary Video 1 shows a part of the robot-assisted preparation of a density gradient.) (B) Manual preparation of density gradients • Timing 20 min per density gradient, depending on the experience of the researcher c CRITICAL The preparation of high-quality density gradients is essential in order to obtain high recovery efficiencies and adequate separation of BEVs from contaminants. Therefore, hands-on training is recommended (Box 3).
(i) Carefully transfer 4 ml of the sample containing 50% (wt/vol) iodixanol solution from
Step 19 to the bottom of a thin-walled polypropylene centrifugation tube. (ii) Slowly tilt the tube to 70°and carefully transfer (drop by drop) 4 ml of the 40% (wt/vol) iodixanol solution to the surface of the liquid (close to the opening of the tube; Fig. 5c ). Preferentially, use a P1000 pipette (transfer 4 × 1,000 µl). (iii) Carefully transfer (drop by drop) 4 ml of the 20% (wt /vol) iodixanol solution to the surface of the liquid (close to the opening of the tube). Preferentially, use a P1000 pipette (transfer 4 × 1,000 µl). (iv) Carefully transfer (drop by drop) 3.5 ml of the 10% (wt/vol) iodixanol solution to the surface of the liquid (close to the opening of the tube). Preferentially, use a P1000 pipette (transfer 4 × 875 µl). (v) Carefully transfer (drop by drop) 1 ml of endotoxin-free PBS to the surface of the liquid (close to the opening of the tube). Preferentially, use a P1000 pipette. c CRITICAL STEP We recommend not to place the tube upright between these different steps because this negatively affects the density-gradient quality. In the case of preparation of several density gradients, place the finished gradients upright on ice or, preferentially, use other pre-cooled (−20°C) devices especially made for tubes ( Fig. 5d ). ? TROUBLESHOOTING 21 Open the lid of the ultracentrifuge and place the pre-cooled SW 32.1 Ti rotor into the ultracentrifuge. Close the lid. 22 Carefully place the centrifugation tube from Step 20 into the pre-cooled bucket. 23 Open the lid and carefully place the buckets into the rotor. Symmetrically balance the load and use a counterbalance when needed. A tube filled with Tween 20 can be used as a counterbalance because its density is similar to that of the iodixanol density gradient. Close the lid. 24 Enter the following parameters into the software of the ultracentrifuge:
Parameter Value
Speed 100,000g Time 18 h Temperature 4°C Acceleration profile 0 (0: maximum; 10: minimum) Deceleration profile 9 (0: maximum; 10: minimum) c CRITICAL STEP A change in one of these parameters will inevitably lead to a density shift in the final fractions. The acceleration occurs as quickly as possible, and the deceleration profile is the second-slowest program provided by the Beckman Coulter software of the Optima XPN-80 ultracentrifuge. Do not use a deceleration profile of 10 because of the extreme length of time it would take for the rotor to come to a stop (no braking is applied). 25 Start the ultracentrifuge. 26 After completion of the ultracentrifugation, open the lid and carefully place the buckets in a rack. In the case of several density gradients, place only one bucket in the rack and leave the others in the cold ultracentrifuge if you proceed with option B in step 27. If option B is to be followed in Step 28, do not turn off the ultracentrifuge; instead, bring the buckets to 4°C after the ultracentrifugation and again cool the centrifuge to 4°C. 27 Take the centrifugation tube out of the bucket and perform a robot-assisted (option A) or manual (option B) density-gradient fraction collection. As in Step 20, we recommend using option A to achieve higher protocol repeatability and increase standardization.
(A) Robot-assisted density-gradient fraction collection • Timing 8 min per density gradient c CRITICAL To ensure sterility during the density-gradient fraction collection, we recommend using an automatic liquid handler equipped with a positive pressure HEPA enclosure. (i) Start the robot (e.g., a Biomek 400 automated workstation) and software. (ii) Open the fraction collection script. The script was designed in close collaboration with Beckman Coulter. (iii) Place the tip boxes, pipettor, sample rack and pre-cooled tube rack with centrifugal tube into one of the 12 deck positions of the workstation (Fig. 5d ). (iv) Start the fraction collection script.
(v) Pool density fractions 8 and 9 (these contain the BEVs) and immediately place them on ice.
(Fractions are numbered starting from the top.) (B) Manual density-gradient fraction collection • Timing 15 min per density gradient, depending on the experience of the researcher (i) Carefully collect 1-ml fractions from the top of the centrifugation tube by slowly pipetting 1 ml from the center of the liquid surface of the density gradient. Use a P1000 pipette with precise control to transfer the density fractions to sterile sample tubes and immediately place them on ice. The final density of the collected fractions can be determined by making a standard curve of the absorbance values at 340 nm of 1:1 aqueous dilutions of 5, 10, 20 and 40% iodixanol. c CRITICAL STEP Hold the centrifugation tube between your thumb and forefinger and make sure the tube stays upright. ? TROUBLESHOOTING (ii) Pool density fractions 8 and 9 (as these contain the BEVs) and immediately place them on ice. Depending on the research goal, other density fractions can also be collected and processed in the same way. For example, EEVs are present in lower-density fractions 5-7, as previously shown 6 .
BEV recovery
28 Depending on the planned downstream characterization, we propose two different procedures for retrieving BEVs from density fractions. OptiPrep remnants in separated BEVs can interfere with downstream approaches such as functional activity assays 39 . Complete removal of iodixanol is desirable. Iodixanol removal can be achieved by SEC (option A) 35 . In the case that only robust detection analyses are intended (e.g., western blotting), option B (ultracentrifugation) can be performed to minimize the hands-on time. We do recommend option A because the highest BEV specificity is obtained with this procedure, as evidenced in Fig. 4c . (A) SEC • Timing 30 min (i) Place the SEC column into a tripod (see Fig. 5e for experimental setup). The detailed description of the preparation of the column can be found in the 'Equipment setup' section. (ii) Pre-rinse the column with endotoxin-free PBS (use at least 10 ml of PBS). c CRITICAL STEP When loading PBS (or the sample) onto the column, make sure you do not disturb the Sepharose beads in the column. Load drop by drop and close to the surface of the column (Supplementary Video 2) . c CRITICAL STEP Before sample loading, collect the eluate in a translucent vial, because this is the time point at which to check whether the column is leaking Sepharose beads. The presence of beads in the eluate can be easily checked by phase-contrast microscopy imaging, because these beads have a size of 60-200 µm. ? TROUBLESHOOTING (iii) Load pooled density fractions 8 and 9 (= 2 ml) from Step 27 onto the column. (iv) Immediately after loading the sample onto the column, start collecting 1-ml SEC fractions.
The first 3 ml is void volume, SEC fractions 4-7 contain the BEVs. Iodixanol elution starts with SEC fraction 8 35 . c CRITICAL STEP Ensure that the SEC column never becomes dry. Reload with endotoxinfree PBS when the entire sample has penetrated the column. (viii) Take the centrifugation tube out of the bucket and carefully remove and discard all the supernatant until only 30 µl remains in the middle of the bottom of the tube. c CRITICAL STEP The pellet is easily disturbed or pipetted; therefore, careful removal of the supernatant is recommended. Training to carry out this step is essential (Box 3). (ix) Collect the pellet and dilute it to 100 µl with pre-cooled (4°C) endotoxin-free PBS. In our experience, a substantial proportion of BEVs stick to the bottom of the tube after pellet collection. Therefore, we recommend pipetting the pellet up and down before collection and rinse the bottom of the tube with the PBS used for dilution. j PAUSE POINT BEVs can be used immediately or stored at −80°C for up to several months.
BEV characterization 29 We have included different procedures for BEV characterization; use option A for NTA, option B for TEM, option C for western blotting, option D for LPS activity measurements, option E for TLR2/TLR4 activity measurements, option F for PBMC stimulation experiments, or option G for proteomic analysis. We use a BEV suspension with a final volume of 100 µl. As described in Step 3, we recommend concurrently performing orthogonal biophysical separation of a blank sample, followed by biochemical characterization of the final sample. This blank sample serves as a protocol control and will allow detection of any contamination. (A) NTA • Timing 10 min per sample (i) Make a 1:10 serial dilution of the BEV suspension in PBS to reach a concentration within the detection range of the device (e.g., for the NanoSight LM10 instrument: 3 × 10 8 -1 × 10 9 particles/ml). In our experience, a minimal 1:5,000 dilution is required if starting from 1.25 g of stool sample. (ii) Perform NTA on the diluted samples according to the instructions provided by the manufacturer. Using a NanoSight LM10 device, record at least three 60-s videos and analyze them with camera level 13 and detection threshold 3. Preferably, a syringe pump system (recommended infusion rate: 20 arbitrary units) is integrated into the setup in order to increase the statistical power of the measurement. (v) Perform western blotting as detailed in ref. 40 . We recommend staining the samples for BEV markers (e.g., OmpA), contaminating EEV markers (e.g., Flotillin-1, CD9 and ALIX) and contaminating protein markers (e.g., Flagellin). ? TROUBLESHOOTING (D) LPS activity measurements • Timing 2 h (i) Make a 1:10 serial dilution of the BEV suspension. In our experience, the lower detection limit of Gram-negative BEVs for LPS activity measurement is 1.56 × 10 5 BEVs/ml. (ii) Perform the LAL assay according to the manufacturer's guidelines.
c CRITICAL STEP Prepare a fresh set of dilutions from the stock endotoxin solution before each test to set up a standard curve. All controls, samples and endotoxin standard series should be tested at least in duplicate. Temperature and reaction timings of the assay are critical. (iii) Analyze the samples using the Paradigm Detection Platform with SoftMax Pro 6.1 software.
? TROUBLESHOOTING (E) TLR2/TLR4 activity measurements • Timing 18 h (i) Make a 1:10 serial dilution of the BEV suspension. In our experience, the lower detection limit of BEVs for TLR4 activity measurement is 4.67 × 10 6 Gram-negative BEVs/ml and for TLR2 activity measurement is 10 8 stool-derived BEVs/ml. (ii) Perform the TLR2/TLR4 activity measurements using HEK293 reporter cell lines according to the instructions provided by the manufacturer. c CRITICAL STEP As clearly stated in the datasheet for these reporter cell lines, use low-passage cells and passage the cells when 70-80% confluency is reached in order to guarantee the quality and sensitivity of the cells. Confluency can be determined in a standardized and objective way using the confluency mask tool of the IncuCyte technology. (iii) Analyze the samples with the Paradigm Detection Platform using SoftMax Pro 6.1 software.
? TROUBLESHOOTING (F) PBMC stimulation experiments • Timing 1 d 4 h (i) Isolate PBMCs, starting from 4 ml of blood, using Ficoll-Paque PLUS density-gradient medium according to the manufacturer's guidelines. ! CAUTION Experiments using human samples must conform to local and national regulations. In this study, collection of blood samples was done according to Ethical Committee of Ghent University Hospital approvals EC/2014/0655 and EC/2017/0882 and in accordance with the relevant guidelines. Informed consent must be obtained when using patient blood samples. (ii) Dilute the PBMCs to 1.33 × 10 7 PBMCs/ml with pre-warmed (37°C) RPMI cell culture medium supplemented with 5% FCS. (iii) Add 150 µl of the PBMC solution to a well of a 96-well plate and let the PBMCs adhere for 2 h (37°C, 5% CO 2 ). (iv) Carefully remove the cell medium and replace it with pre-warmed (37°C) serum-free RPMI. Repeat this step two times. c CRITICAL STEP Slow removal of the medium is essential in order to avoid extensive loss of PBMCs.
(v) Add BEVs to the PBMCs. In our experience, concentrations down to 10 7 BEVs/ml can be used. (vi) Incubate for at least 24 h. Note that some of the cytokines are released immediately after PBMC stimulation (e.g., tumor necrosis factor (TNF)-α; Supplementary Fig. 1 ). In addition to the short stimulation experiment, we encourage researchers to record videos to visualize the PBMC stimulation and differentiation. Therefore, use a live cell analysis system and record a video by taking a picture every 2 h ( Supplementary Videos 3 and 4 ). 42 ), including different isoforms. We also recommend the use of automatic metagenome annotation servers such as GhostKOALA 43 .
? TROUBLESHOOTING
Troubleshooting
Troubleshooting advice can be found in Table 1 . 
Anticipated results
We demonstrated the ability of orthogonal biophysical separation and biochemical characterization to analyze BEVs in human body fluids.
Size-based separation of large-volume resuspended stool samples by low-speed centrifugation and ultrafiltration results in depletion of bacteria, eukaryotic cell debris and soluble components that are <10 kDa, such as proteins and LPS. Size-based separation of blood plasma by low-speed centrifugation and SEC results in depletion of blood cells, HDLs, soluble proteins and LPS (Fig. 1 ). Sizebased separation reduces the complexity of body fluids, resulting in a crude extract that enables density-based separation. The unique buoyant nature of BEVs allows density separation from fibers, protein aggregates and EEVs in stool; and from VLDLs and LDLs, chylomicrons, protein aggregates and EEVs in blood (Fig. 1) . The unique higher density of BEVs separates them from lower-density EEVs in stool (the majority coming from gut epithelial cells) and blood (the majority coming from platelets) 6, 35 .
The most sensitive characterization method, TEM or immuno-EM, reveals the ultrastructure of BEVs and identifies the presence of single and double bilayered BEVs (Figs. 3 and 4c ). The observation of double bilayered BEVs suggests the presence of outer-inner membrane vesicles (OIMVs) derived from Gram-negative bacteria. The biogenesis of OIMVs requires that the inner membrane Sample is too diluted Repeat the NTA measurement on a less diluted sample. The particle concentration should be within the detection range of the device (e.g., for the NanoSight LM10 instrument: 3 × 10 8 to 1 × 10 9 particles/ml) NanoSight is not sensitive enough Increase the camera level before NTA measurement. This level determines the brightness of the image by using preset combinations of shutter and gain. Be aware that background signals will also be picked up more quickly. 29B(viii) High amount of contaminants visible Incomplete separation of contaminants (e.g., fibers and flagella) from BEVs In Step 28, perform SEC (option A) instead of ultracentrifugation (option B; see Fig. 4c ).
Optionally repeat option A several times, because this may further increase the BEV purity 29D(iii), 29E(iii)
Duplicates do not have similar absorbance values
Inaccurate pipetting
Repeat the assay and pipette accurately (consider the use of a multichannel pipette) Standard curve is not linear (whether or not using a logarithmic scale)
Inaccurate pipetting and/or improper preparation of the standard solutions
Repeat the assay and pipette accurately (consider the use of a multichannel pipette). Be sure the standard solutions are thoroughly mixed protrude into the periplasm, allowing cytoplasmic contents to enter the vesicle, which is eventually pinched off from the cell surface together with a surrounding outer membrane 7 . These inner membrane proteins and cytoplasmic proteins are identified by mass spectrometry-based proteomics. The presence of chromosomal DNA in OIMVs derived from body fluids needs further investigation. The simultaneous presence of LPS-containing outer membrane vesicles (OMVs) or OIMVs and LTA-containing cytoplasmic membrane vesicles (CMVs) is evidenced by endotoxin assays and TLR2/4 reporter assays. These assays show intermediate sensitivity, with the LAL assay being the most sensitive (>10 5 Gram-negative BEVs) and the TLR2 reporter assay being the least sensitive (>10 8 stool-derived BEVs; Fig. 3 ).
Starting from fresh stool samples, an overall high yield of BEVs can be expected. In our experience, a minimal amount of 2.5 × 10 11 BEVs per gram of wet stool (BSS category 3 or 4) is obtained if no saturation of the stool sample in PBS occurred in Step 3 of the Procedure (Fig. 4b) . For blood plasma from patients with intestinal barrier dysfunction (IBD patients), an overall yield slightly lower than 10 6 BEVs/ml of plasma is obtained. Low-yield BEV samples are especially prone to misinterpretation because of potential contamination derived from laboratory reagents and environments; such samples require appropriate negative and positive controls, as discussed in the 'Experimental design' section. The recovery efficiencies of the orthogonal biophysical separation methods must be considered as well, and we estimate that an efficiency of 30% is achieved when using a combination of SEC and density-gradient centrifugation 24 . However, a recovery efficiency of only 5% is obtained when ultracentrifugation is performed in Step 28.
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